2024-11-19 02:37:08
CStone Announces Preliminary Results from a Bridging Study of Avapritinib in Chinese Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors at the 2020 CSCO Annual Meeting
Corporate/ 2023-07-23
CStone Announces Preliminary Results fro...

Avapritinib has demonstrated strong anti-tumor activity in Chinese patients with PDGFRA D842V mutant GIST

CStone Pharmaceuticals Announces Updated Results from Two Studies of Its Anti-PD-L1 Monoclonal Antibody Sugemalimab (CS1001) At 2020 CSCO Annual Meeting
Corporate/ 2023-07-23
CStone Pharmaceuticals Announces Updated...

CS1001-201 study demonstrated an objective response rate (ORR) of 44.7%,a complete response (CR) rate of 31.6%,median overall survival (mOS)...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release